Smoking cessation medications
Pro Research Analysisby 
Searched over 200M research papers
First-Line Smoking Cessation Medications: Nicotine Replacement, Bupropion, and Varenicline
The main first-line medications for smoking cessation are nicotine replacement therapy (NRT), bupropion, and varenicline. NRT is available in several forms, including patches, gum, lozenges, nasal spray, and inhalers, and helps reduce withdrawal symptoms by providing controlled doses of nicotine without the harmful effects of smoking 139. Bupropion, an atypical antidepressant, and varenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, are also widely used. Varenicline has been shown to be more effective than bupropion and NRT in helping people quit smoking, but all three are considered effective first-line options 1346+1 MORE.
Second-Line and Emerging Smoking Cessation Medications
When first-line treatments are not effective or suitable, second-line medications such as nortriptyline (a tricyclic antidepressant) and clonidine (an antihypertensive) may be used. These are generally reserved for cases where other treatments have failed due to their side effect profiles 13. Newer medications like cytisinicline, another partial agonist at nicotinic receptors, have shown promise in recent trials, demonstrating higher abstinence rates and good tolerability compared to placebo .
Effectiveness and Comparative Efficacy of Smoking Cessation Medications
Bupropion and nortriptyline both approximately double the odds of quitting compared to placebo, and their effectiveness is similar to that of NRT 246. However, varenicline is generally more effective than bupropion, with higher continuous abstinence rates reported in clinical trials 168. Cytisinicline has also shown significant efficacy, with abstinence rates higher than placebo and a reduction in nicotine cravings . Combining bupropion with NRT may increase quit rates, but evidence for additional long-term benefit is limited 246.
Safety and Side Effects of Smoking Cessation Medications
Most first-line medications are well tolerated, but each has specific side effects. Bupropion is associated with a small risk of seizures (about 1 in 1000 users) and possible sleep disturbances such as insomnia, especially when combined with other agents 4610. Nortriptyline can cause somnolence and has the potential for serious side effects, though these are rare in smoking cessation trials 1610. Varenicline may cause abnormal dreams and, rarely, neuropsychiatric symptoms, but recent evidence suggests it is generally safe 810. Cytisinicline has been well tolerated in recent studies, with no serious treatment-related adverse events reported . Selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) have not shown significant benefit for smoking cessation and are not recommended 46.
Special Considerations: Mental Health and Sleep-Related Side Effects
For individuals with mental health disorders, first-line medications remain effective, but careful monitoring is needed due to possible interactions with psychiatric medications and the potential impact on mental health symptoms . Sleep-related side effects, such as insomnia, abnormal dreams, and somnolence, are more common with bupropion, varenicline, and nortriptyline, and should be considered when choosing a medication .
Population Impact and the Need for Improved Medications
Despite the proven efficacy of current smoking cessation medications, their overall impact on population smoking rates is limited. Even under ideal conditions, only a small percentage of smokers quit permanently with current medications, highlighting the need for more effective treatments and broader access to behavioral support 78.
Conclusion
Nicotine replacement therapy, bupropion, and varenicline are the main evidence-based medications for smoking cessation, with nortriptyline and clonidine as second-line options. Newer agents like cytisinicline show promise. While these medications are effective and generally safe, their impact on population-level smoking rates is modest, and side effects—especially sleep-related—should be considered. Individualized treatment plans and ongoing monitoring are essential for optimal outcomes, particularly for those with mental health conditions. Continued research and development of more effective smoking cessation medications remain a priority.
Sources and full results
Most relevant research papers on this topic